Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269275 | 0.92 | KDM4E (0.35) | PIK3CDPDK2KDM4ETDP1 | |
| SCHEMBL31269396 | 0.92 | PIK3CD (0.33) | PIK3CDKDM4ETDP1 | |
| SCHEMBL31268819 | 0.92 | PIK3CD (0.36) | PIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL31268798 | 0.90 | MEN1 (0.34) | PIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL31268938 | 0.90 | KDM4E (0.35) | PIK3CDKDM4ETDP1ALDH1A1HSD17B10 | |
| SCHEMBL31269457 | 0.90 | SMN1; SMN2 (0.34) | PIK3CD | |
| SCHEMBL31268824 | 0.90 | PIK3CD (0.34) | PIK3CDPDK2KCNH2SCN5ASCN9A | |
| SCHEMBL31268748 | 0.89 | PIK3CD (0.35) | PIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL30983502 | 0.89 | NPC1 (0.38) | PIK3CDPDK2KDM4EALDH1A1HPGD | |
| SCHEMBL31269352 | 0.88 | PIK3CD (0.37) | PIK3CDKDM4ETDP1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |